BioMarin Pharmaceutical (NASDAQ: BMRN) and Syros Pharmaceuticals (NASDAQ:SYRS) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.

Risk and Volatility

BioMarin Pharmaceutical has a beta of 1.82, suggesting that its share price is 82% more volatile than the S&P 500. Comparatively, Syros Pharmaceuticals has a beta of -3.72, suggesting that its share price is 472% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for BioMarin Pharmaceutical and Syros Pharmaceuticals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioMarin Pharmaceutical 0 6 16 0 2.73
Syros Pharmaceuticals 0 1 6 0 2.86

BioMarin Pharmaceutical presently has a consensus price target of $113.80, indicating a potential upside of 38.80%. Syros Pharmaceuticals has a consensus price target of $26.14, indicating a potential upside of 111.32%. Given Syros Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe Syros Pharmaceuticals is more favorable than BioMarin Pharmaceutical.

Valuation & Earnings

This table compares BioMarin Pharmaceutical and Syros Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BioMarin Pharmaceutical $1.12 billion 12.89 -$630.21 million ($0.90) -91.10
Syros Pharmaceuticals $320,000.00 1,016.66 -$47.74 million ($2.01) -6.15

Syros Pharmaceuticals has lower revenue, but higher earnings than BioMarin Pharmaceutical. BioMarin Pharmaceutical is trading at a lower price-to-earnings ratio than Syros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.


This table compares BioMarin Pharmaceutical and Syros Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BioMarin Pharmaceutical -12.45% -4.60% -3.09%
Syros Pharmaceuticals N/A -62.01% -55.65%

Insider and Institutional Ownership

99.3% of BioMarin Pharmaceutical shares are held by institutional investors. Comparatively, 58.0% of Syros Pharmaceuticals shares are held by institutional investors. 1.9% of BioMarin Pharmaceutical shares are held by insiders. Comparatively, 33.6% of Syros Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.


BioMarin Pharmaceutical beats Syros Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A). The Company is conducting clinical trials on various product candidates for the treatment of various diseases. Its clinical product candidates include Brineura, pegvaliase, vosoritide, BMN 270 and BMN 250.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines. The Company’s drug programs include SY-1425 (retinoic acid receptor alpha (RARa) agonist) and SY-1365 (cyclin-dependent kinase 7 (CDK7) inhibitor). SY-1425 (tamibarotene) is an oral, potent and selective agonist, or activator, of the transcription factor RARa. SY-1365 is a small molecule inhibitor of the transcriptional kinase known as CDK7. The Company is using its platform to analyze gene expression programs across additional cancers, inflammatory diseases and other diseases to identify optimal points of therapeutic intervention in specific subsets of patients.

Receive News & Ratings for BioMarin Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.